Literature DB >> 35812666

Electroconvulsive therapy plays an irreplaceable role in treatment of major depressive disorder.

Mei-Lin Ma1, Lian-Ping He2.   

Abstract

Major depressive disorder is a serious and common neuropsychiatric disorder that affects more than 350 million people worldwide. Electroconvulsive therapy is the oldest and most effective treatment available for the treatment of severe major depressive disorder. Electroconvulsive therapy modifies structural network changes in patients with major depressive disorder and schizophrenia. And it can also affect neuroinflammatory responses and may have neuroprotective effects. Electroconvulsive therapy plays an irreplaceable role in the treatment of major depressive disorder. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Depression; Electroconvulsive therapy; Major depressive disorder; Somatic cell therapy

Year:  2022        PMID: 35812666      PMCID: PMC9210908          DOI: 10.12998/wjcc.v10.i16.5515

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.534


Core Tip: Electroconvulsive therapy has been shown to be very useful for the acute treatment of major depressive, manic, and mixed states, especially those with a high degree of suicide, as well as catatonic and drug-resistant depression. It should not be seen as a second line of defense after drug therapy.

TO THE EDITOR

In a recent review, Xin-Ke Li et al[1] expounded the neuroimaging research progress of electroconvulsive therapy (ECT) for major depressive disorder. The authors concluded that the neurobiological mechanism of ECT may be to modulate the functional activity and connectivity or neural structural plasticity of specific brain regions to normal levels for therapeutic effect. We fully agree with the authors and hereby elaborate on the importance and potential of ECT for major depressive disorder. ECT mainly achieves therapeutic effects by increasing the synthesis and uptake of norepinephrine in the body and improving the sensitivity of serotonergic neurons. The prevailing view on the mechanism of ECT is that a cascade of reactions is triggered by electrical stimulation of specific areas of the brain. Consequently, neuronal synaptic plasticity and the levels of various neurotrophic factors and synaptic cleft transmitters are altered. Therefore, ECT has a significant therapeutic effect on a variety of mental disorders[2]. A series of studies have proved that ECT is especially suitable for major depressive disorder[3], manic acute episodes, and schizophrenia, especially some acute patients, those with acute affective symptoms, and catatonic patients[3,4]. ECT has the function of regulating the neuroinflammatory response. When subjected to external stress, there is an inflammatory response that activates indole-amine 2,3-dioxygenase and degrades TRP to kynurenine (KYN), which is metabolized to kynurenic acid (KYNA) and 3-hydroxykynurenine (3-HK). Then, KYNA and 3-HK are converted to quinolinic acid[5]. 3-HK and quinolinic acid have neurotoxic effects on the central nervous system, while KYNA is neuroprotective. Major depressive disorder exacerbates the immune inflammatory response, leading to an increase in BDNF. Several studies have shown that ECT increases KYNA levels[6]. This suggests that ECT may have neuroprotective effects. In addition, accumulating neuroimaging evidence suggests that ECT modulates medial temporal and prefrontal cortical regions in major depressive disorder. Source-based morphometry (a multivariate statistical approach for structural data analysis) revealed that the medial temporal lobe network (including the hippocampus and parahippocampal cortex) was significantly increased after ECT[7]. What’s more, a study shows that brain plasticity is induced by changes in gray matter volume (GMV) during treatment for schizophrenia[8]. GMV was determined using voxel-based morphometry whole-brain analysis. These studies provide a broader perspective on the mechanism of action of ECT in the treatment of depression. In general, ECT has played a very important role in the treatment of some depressive disorders, especially major depressive disorders. In the past decade, however, the role of physical therapy in some neuropsychiatric disorders has been underestimated or partially ignored. Most practitioners only consider ECT when a patient has failed to respond to many medication therapies. Such attempts can last months or years, delaying treatment while also increasing the patient's mental instability and prolonging their suffering. And due to a series of reasons such as ideology[9] and social environment, the role of ECT has not been fully exerted. ECT should not be seen as a last resort for psychiatric treatment.
  9 in total

Review 1.  Electroconvulsive Therapy in Italy: Will Public Controversies Ever Stop?

Authors:  Claudio Buccelli; Pierpaolo Di Lorenzo; Mariano Paternoster; Giordano DʼUrso; Vincenzo Graziano; Massimo Niola
Journal:  J ECT       Date:  2016-09       Impact factor: 3.635

Review 2.  Key updates in the clinical application of electroconvulsive therapy.

Authors:  Richard D Weiner; Irving M Reti
Journal:  Int Rev Psychiatry       Date:  2017-04-13

Review 3.  Electroconvulsive therapy in adolescents with the catatonia syndrome: efficacy and ethics.

Authors:  Angèle Consoli; Maha Benmiloud; Lee Wachtel; Dirk Dhossche; David Cohen; Olivier Bonnot
Journal:  J ECT       Date:  2010-12       Impact factor: 3.635

Review 4.  Electroconvulsive therapy for depression.

Authors:  Sarah H Lisanby
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

5.  ECT-induced brain plasticity correlates with positive symptom improvement in schizophrenia by voxel-based morphometry analysis of grey matter.

Authors:  Junjie Wang; Yingying Tang; Adrian Curtin; Mengqing Xia; Xiaochen Tang; Yuanqiao Zhao; Yu Li; Zhenying Qian; Jianhua Sheng; Tianhong Zhang; Yuping Jia; Chunbo Li; Jijun Wang
Journal:  Brain Stimul       Date:  2018-11-17       Impact factor: 8.955

Review 6.  Electroconvulsive therapy, depression, the immune system and inflammation: A systematic review.

Authors:  Antoine Yrondi; Marie Sporer; Patrice Péran; Laurent Schmitt; Christophe Arbus; Anne Sauvaget
Journal:  Brain Stimul       Date:  2017-10-19       Impact factor: 8.955

7.  Structural network changes in patients with major depression and schizophrenia treated with electroconvulsive therapy.

Authors:  Robert Christian Wolf; Henrike Maria Nolte; Dusan Hirjak; Stefan Hofer; Ulrich Seidl; Malte Sebastian Depping; Bram Stieltjes; Klaus Maier-Hein; Fabio Sambataro; Philipp Arthur Thomann
Journal:  Eur Neuropsychopharmacol       Date:  2016-07-12       Impact factor: 4.600

8.  Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients.

Authors:  Lilly Schwieler; Martin Samuelsson; Mark A Frye; Maria Bhat; Ina Schuppe-Koistinen; Oscar Jungholm; Anette G Johansson; Mikael Landén; Carl M Sellgren; Sophie Erhardt
Journal:  J Neuroinflammation       Date:  2016-02-29       Impact factor: 8.322

Review 9.  Current progress in neuroimaging research for the treatment of major depression with electroconvulsive therapy.

Authors:  Xin-Ke Li; Hai-Tang Qiu
Journal:  World J Psychiatry       Date:  2022-01-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.